IgG Fc Engineering to Modulate Antibody Effector Functions

Overview

Journal Protein Cell

Publisher Oxford University Press

Specialties Biochemistry
Cell Biology

Date 2017 Oct 8

PMID 28986820

Citations 185

Authors

Xinhua Wang

Mary Mathieu

Randall J Brezski

Affiliations

Soon will be listed here.

Abstract

Therapeutic monoclonal antibodies are among the most effective biotherapeutics to date. An important aspect of antibodies is their ability to bind antigen while at the same time recruit immune effector functions. The majority of approved recombinant monoclonal antibody therapies are of the human IgG1 subclass, which can engage both humoral and cellular components of the immune system. The wealth of information generated about antibodies has afforded investigators the ability to molecularly engineer antibodies to modulate effector functions. Here, we review various antibody engineering efforts intended to improve efficacy and safety relative to the human IgG isotype. Further, we will discuss proposed mechanisms by which engineering approaches led to modified interactions with immune components and provide examples of clinical studies using next generation antibodies.

Citing Articles

Design of a fragment crystallizable-engineered tetravalent bispecific antibody targeting programmed cell death-1 and vascular endothelial growth factor with cooperative biological effects.

Zhong T, Zhang L, Huang Z, Pang X, Jin C, Liu W iScience. 2025; 28(3):111722.

PMID: 40034861 PMC: 11872405. DOI: 10.1016/j.isci.2024.111722.

Biomembrane structure at the molecular level and its application in precision medicine.

Wang Z, Tian Z, Gao J, Wang H Biophys Rev (Melville). 2025; 6(1):011306.

PMID: 39980736 PMC: 11839234. DOI: 10.1063/5.0213964.

CD22 modulation alleviates amyloid β-induced neuroinflammation.

Mai Y, Zhang Q, Fung C, Leung S, Chong C J Neuroinflammation. 2025; 22(1):32.

PMID: 39910617 PMC: 11800469. DOI: 10.1186/s12974-025-03361-2.

An antibody cocktail targeting two different CD73 epitopes enhances enzyme inhibition and tumor control.

Xu J, Chen S, He Y, Zhu X, Wang Y, Ye Z Nat Commun. 2024; 15(1):10872.

PMID: 39738003 PMC: 11685497. DOI: 10.1038/s41467-024-55207-9.

Model acetylcholinesterase-Fc fusion glycoprotein biotechnology system for the manufacture of an organophosphorus toxicant bioscavenging countermeasure.

Biel T, Faison T, Matthews A, Ortega-Rodriguez U, Falkowski V, Meek E Bioeng Transl Med. 2024; 9(5):e10666.

PMID: 39553427 PMC: 11561780. DOI: 10.1002/btm2.10666.

References

Teeling J, Mackus W, Wiegman L, van den Brakel J, Beers S, French R . The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20. J Immunol. 2006; 177(1):362-71. DOI: 10.4049/jimmunol.177.1.362. View

MARTIN W, West Jr A, Gan L, Bjorkman P . Crystal structure at 2.8 A of an FcRn/heterodimeric Fc complex: mechanism of pH-dependent binding. Mol Cell. 2001; 7(4):867-77. DOI: 10.1016/s1097-2765(01)00230-1. View

Beck A, Reichert J . Marketing approval of mogamulizumab: a triumph for glyco-engineering. MAbs. 2012; 4(4):419-25. PMC: 3499336. DOI: 10.4161/mabs.20996. View

Tao M, Morrison S . Studies of aglycosylated chimeric mouse-human IgG. Role of carbohydrate in the structure and effector functions mediated by the human IgG constant region. J Immunol. 1989; 143(8):2595-601. View

Blank U, Launay P, Benhamou M, Monteiro R . Inhibitory ITAMs as novel regulators of immunity. Immunol Rev. 2009; 232(1):59-71. DOI: 10.1111/j.1600-065X.2009.00832.x. View

Jefferis R, Lund J, POUND J . Molecular definition of interaction sites on human IgG for Fc receptors (huFc gamma R). Mol Immunol. 1990; 27(12):1237-40. DOI: 10.1016/0161-5890(90)90027-w. View

Zalevsky J, Chamberlain A, Horton H, Karki S, Leung I, Sproule T . Enhanced antibody half-life improves in vivo activity. Nat Biotechnol. 2010; 28(2):157-9. PMC: 2855492. DOI: 10.1038/nbt.1601. View

Cartron G, Dacheux L, Salles G, Solal-Celigny P, Bardos P, Colombat P . Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood. 2002; 99(3):754-8. DOI: 10.1182/blood.v99.3.754. View

Loyau J, Malinge P, Daubeuf B, Shang L, Elson G, Kosco-Vilbois M . Maximizing the potency of an anti-TLR4 monoclonal antibody by exploiting proximity to Fcγ receptors. MAbs. 2014; 6(6):1621-30. PMC: 4622919. DOI: 10.4161/19420862.2014.975098. View

10.

Burmeister W, Gastinel L, Simister N, BLUM M, Bjorkman P . Crystal structure at 2.2 A resolution of the MHC-related neonatal Fc receptor. Nature. 1994; 372(6504):336-43. DOI: 10.1038/372336a0. View

11.

Robbie G, Criste R, DallAcqua W, Jensen K, Patel N, Losonsky G . A novel investigational Fc-modified humanized monoclonal antibody, motavizumab-YTE, has an extended half-life in healthy adults. Antimicrob Agents Chemother. 2013; 57(12):6147-53. PMC: 3837853. DOI: 10.1128/AAC.01285-13. View

12.

Lo M, Kim H, Tong R, Bainbridge T, Vernes J, Zhang Y . Effector-attenuating Substitutions That Maintain Antibody Stability and Reduce Toxicity in Mice. J Biol Chem. 2017; 292(9):3900-3908. PMC: 5339770. DOI: 10.1074/jbc.M116.767749. View

13.

Brambell F . The transmission of immunity from mother to young and the catabolism of immunoglobulins. Lancet. 1966; 2(7473):1087-93. DOI: 10.1016/s0140-6736(66)92190-8. View

14.

Szili D, Cserhalmi M, Banko Z, Nagy G, Szymkowski D, Sarmay G . Suppression of innate and adaptive B cell activation pathways by antibody coengagement of FcγRIIb and CD19. MAbs. 2014; 6(4):991-9. PMC: 4171032. DOI: 10.4161/mabs.28841. View

15.

Ghetie V, Hubbard J, Kim J, Tsen M, Lee Y, Ward E . Abnormally short serum half-lives of IgG in beta 2-microglobulin-deficient mice. Eur J Immunol. 1996; 26(3):690-6. DOI: 10.1002/eji.1830260327. View

16.

Uppal H, Doudement E, Mahapatra K, Darbonne W, Bumbaca D, Shen B . Potential mechanisms for thrombocytopenia development with trastuzumab emtansine (T-DM1). Clin Cancer Res. 2014; 21(1):123-33. DOI: 10.1158/1078-0432.CCR-14-2093. View

17.

Fahey J, Robinson A . FACTORS CONTROLLING SERUM GAMMA-GLOBULIN CONCENTRATION. J Exp Med. 1963; 118:845-68. PMC: 2137682. DOI: 10.1084/jem.118.5.845. View

18.

Monnet E, Lapeyre G, van Poelgeest E, Jacqmin P, de Graaf K, Reijers J . Evidence of NI-0101 pharmacological activity, an anti-TLR4 antibody, in a randomized phase I dose escalation study in healthy volunteers receiving LPS. Clin Pharmacol Ther. 2016; 101(2):200-208. DOI: 10.1002/cpt.522. View

19.

Presta L . Molecular engineering and design of therapeutic antibodies. Curr Opin Immunol. 2008; 20(4):460-70. DOI: 10.1016/j.coi.2008.06.012. View

20.

Thommesen J, Michaelsen T, Loset G, Sandlie I, Brekke O . Lysine 322 in the human IgG3 C(H)2 domain is crucial for antibody dependent complement activation. Mol Immunol. 2001; 37(16):995-1004. DOI: 10.1016/s0161-5890(01)00010-4. View